Absolute monocyte count at diagnosis could improve the prognostic role of early FDG‐PET in classical Hodgkin lymphoma patients

A., Sivina, M., Ferrajoli, A., Ravandi, F., Wierda, W.G., O’Brien, S., Keating, M.J. & Burger, J.A. (2012) Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia, 26, 1576–1583. Ponader, S., Chen, S.S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, M.J., O’Brien, S., Chiorazzi, N. & Burger, J.A. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182–1189. Sivina, M., Hartmann, E., Kipps, T.J., Rassenti, L., Krupnik, D., Lerner, S., LaPushin, R., Xiao, L., Huang, X., Werner, L., Neuberg, D., Kantarjian, H., O’Brien, S., Wierda, W.G., Keating, M.J., Rosenwald, A. & Burger, J.A. (2011) CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood, 117, 1662–1669. Zucchetto, A., Tripodo, C., Benedetti, D., Deaglio, S., Gaidano, G., Del Poeta, G. & Gattei, V. (2010) Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. British Journal of Haematology, 150, 111–113.